Company intelligence / Profile preview

Orbit Genomics

Boulder, Colorado, United States

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Orbit Genomics is advancing AI-driven precision-medicine diagnostics by analyzing short tandem repeats to assess individual risk for complex diseases. Their lung cancer blood test (OrbiSeq-L) has demonstrated high accuracy in a pilot study, and the company received a $2 million NIH/NCI SBIR Phase II grant to further develop it for patients with indeterminate pulmonary nodules.[1][3][5]

Therapeutic areas: CardiovascularOncologyNeurologyOther
Modalities: Diagnostic testPlatform technology (AI-driven genomics)
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Orbit Genomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orbit Genomics.

Explore the full profile